Hereditary ATTR amyloidosisNews & Research

4 curated articles for Hereditary ATTR amyloidosis — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.

ℹ
UniteRare data is compiled from authoritative primary sources (FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, NORD), then processed through automated and AI-assisted extraction pipelines.
Report missing data
  1. Journal of the American Heart Association May 14, 2026

    Pathogenic Characterization of a Novel G47R Transthyretin Mutation in Early-Onset Amyloid Cardiomyopathy.

    Transthyretin amyloid cardiomyopathy is a progressive infiltrative cardiomyopathy driven by the deposition of amyloid fibrils derived from destabilized transthyretin (TTR). Although several pathogenic TTR variants have been characterized, the clinical significance and molecular behavior of rare muta...

    Why it matters: Recent peer-reviewed research on Hereditary ATTR amyloidosis that may be relevant for patients and caregivers.

  2. Neurology May 7, 2026

    Sensitivity of Nerve and Skin Biopsy and Fat Aspirate for Amyloid in Symptomatic Hereditary ATTR Amyloidosis With Peripheral Neuropathy.

    The aim of this study was to compare the sensitivity of nerve biopsy, fat aspirate, and skin biopsy in detecting amyloid in symptomatic hereditary transthyretin amyloidosis with peripheral neuropathy (ATTRv-PN). We identified patients with ATTRv-PN (2012-2023) seen at one of the Mayo Clinic 3 sites ...

    Why it matters: Recent peer-reviewed research on Hereditary ATTR amyloidosis that may be relevant for patients and caregivers.

  3. Frontiers in nuclear medicine Mar 25, 2026

    Pittsburgh compound B positron emission tomography detects cardiomyopathy in hereditary transthyretin amyloidosis patients with negative bone scintigraphy: a pilot study.

    To evaluate the effectiveness of positron emission tomography (PET) with [ 11 C]-Pittsburgh Compound-B ([ 11 C]PiB) for detecting transthyretin amyloid (ATTR) cardiomyopathy in patients with transthyretin gene ( TTR ) variants associated with reduced bone scintigraphy sensitivity, and its ability to...

    Why it matters: Recent peer-reviewed research on Hereditary ATTR amyloidosis that may be relevant for patients and caregivers.

  4. NotableAlnylam Feb 5, 2026

    Alnylam Reports Record $2.8B Revenue from RNAi Portfolio

    Alnylam reported $2.8 billion from RNA interference therapies for hereditary ATTR and other rare diseases.

    Why it matters: RNAi platform proving commercially viable for rare diseases.

More on Hereditary ATTR amyloidosis

Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.